Douglas A. Keller

Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database

Thomas M. Monticello, Thomas W. Jones, Donna M. Dambach et al. · Toxicology and Applied Pharmacology · 2017 · 174 citations

Translational Medicine, Clinical Translation, Translational Relevance +9

An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing

Frank D. Sistare, Daniel Morton, Carl L. Alden et al. · Toxicologic Pathology · 2011 · 152 citations · Full text

Chemoprevention Strategy, Pathology, Toxicology Testing +17

FutureTox II: In vitro Data and In Silico Models for Predictive Toxicology

Thomas B. Knudsen, Douglas A. Keller, Miriam Sander et al. · Toxicological Sciences · 2015 · 129 citations · Full text

Pathology, Toxicological Mechanism, Toxicology Workshop +18

Identification and Characterization of Adverse Effects in 21st Century Toxicology

Douglas A. Keller, Daland R. Juberg, Natasha R. Catlin et al. · Toxicological Sciences · 2012 · 96 citations · Full text

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective

Lorna Ewart, Kristin Fabre, Ananthsrinivas Chakilam et al. · Experimental Biology and Medicine · 2017 · 85 citations · Full text

Tissue Engineering, Pharmaceutical Industry Perspective, Pharmaceutical Research +21